Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 20;18(10):2176-2182.
doi: 10.1021/acschembio.3c00027. Epub 2023 Jun 16.

Antisense Oligonucleotide Activation via Enzymatic Antibiotic Resistance Mechanism

Affiliations

Antisense Oligonucleotide Activation via Enzymatic Antibiotic Resistance Mechanism

Kristie E Darrah et al. ACS Chem Biol. .

Abstract

The structure and mechanism of the bacterial enzyme β-lactamase have been well-studied due to its clinical role in antibiotic resistance. β-Lactamase is known to hydrolyze the β-lactam ring of the cephalosporin scaffold, allowing a spontaneous self-immolation to occur. Previously, cephalosporin-based sensors have been developed to evaluate β-lactamase expression in both mammalian cells and zebrafish embryos. Here, we present a circular caged morpholino oligonucleotide (cMO) activated by β-lactamase-mediated cleavage of a cephalosporin motif capable of silencing the expression of T-box transcription factor Ta (tbxta), also referred to as no tail a (ntla), eliciting a distinct, observable phenotype. We explore the use of β-lactamase to elicit a biological response in aquatic embryos for the first time and expand the utility of cephalosporin as a cleavable linker beyond targeting antibiotic-resistant bacteria. The addition of β-lactamase to the current suite of enzymatic triggers presents unique opportunities for robust, orthogonal control over endogenous gene expression in a spatially resolved manner.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Following enzyme-mediated hydrolysis of the β-lactam ring by β-lactamase (PDB ID 4F6H), the resulting amine intermediate undergoes self-immolation. The release of the 5′-end generates the active, linearized MO capable of hybridizing to its respective target mRNA and silencing gene expression.
Figure 2
Figure 2
(A) Synthetic scheme of the cephalosporin-containing linker 8. (B) Synthesis of the cephalosporin ntla cMO.
Figure 3
Figure 3
(A) Luciferase reporter assay in which luciferase expression is silenced in the presence of linearized MO. (B) Luminescence signal after treatment of the indicated MO. Data represent average ± SEM from three independent experiments. (C) Gel-shift assay showing activation of the circular morpholino sequestering its complementary target DNA (cDNA) in the presence of β-lactamase. (D) Quantification of a time course analysis of cyclic cephalosporin ntla cMO cleavage following incubation with recombinant β-lactamase. Bars represent averages and error bars represent standard deviations from three independent experiments.
Figure 4
Figure 4
(A) Structure of the chromogenic β-lactamase substrate nitrocefin (10), which is hydrolyzed to 11 following β-lactamase catalysis. (B) Western blot analysis of β-lactamase expression in embryos injected with 400 pg of mRNA. (C) Zebrafish lysates analyzed for β-lactamase activity by monitoring production of 11 (absorbance at 486 nm) over time. (D) Initial velocities were determined through a linear regression analysis of the first 10 min of the data presented in (C). The error values indicate the standard deviation of values for the best fit parameters from the linear regression analysis.
Figure 5
Figure 5
(A) Representative images of ntla morphant phenotypes in zebrafish embryos at 24 hpf. Scale bar equals 1 mm. (B) Phenotypic scoring of embryos injected with the indicated morpholino and amount of β-lactamase mRNA.

Similar articles

Cited by

References

    1. Khvorova A.; Watts J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 2017, 35 (3), 238–248. 10.1038/nbt.3765. - DOI - PMC - PubMed
    1. Chakraborty S.; Mehtab S.; Krishnan Y. The predictive power of synthetic nucleic acid technologies in RNA biology. Acc. Chem. Res. 2014, 47 (6), 1710–9. 10.1021/ar400323d. - DOI - PubMed
    1. Havens M. A.; Hastings M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016, 44 (14), 6549–63. 10.1093/nar/gkw533. - DOI - PMC - PubMed
    1. Shen X.; Corey D. R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018, 46 (4), 1584–1600. 10.1093/nar/gkx1239. - DOI - PMC - PubMed
    1. Setten R. L.; Rossi J. J.; Han S. P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discovery 2019, 18 (6), 421–446. 10.1038/s41573-019-0017-4. - DOI - PubMed

Publication types

MeSH terms